GLP-1 Candidacy and Prescribing Considerations in Psoriasis

Dermatology Times has published new guidance on GLP-1 candidacy and prescribing considerations for patients with psoriasis, a signal that incretin-based therapies are moving closer to routine dermatologic conversation.

The coverage addresses a question now landing in dermatology clinics with increasing frequency: which psoriasis patients are appropriate candidates for GLP-1 receptor agonists, and what should clinicians weigh before prescribing or co-managing these agents.

What does this change for dermatologists?

GLP-1 receptor agonists — a class originally developed for type 2 diabetes and now widely used for weight management — have drawn dermatologic interest because of the documented overlap between metabolic disease and psoriasis. Patients with psoriasis carry elevated rates of obesity, insulin resistance and metabolic syndrome, all of which complicate disease control and treatment response.

That comorbidity profile is what puts GLP-1s on the dermatologist's radar. The Dermatology Times coverage walks through candidacy assessment: identifying which patients stand to benefit, and which clinical factors — metabolic status, body weight, concurrent psoriasis therapy — should shape the decision.

The prescribing picture

Beyond candidacy, the article lays out prescribing considerations for clinicians who either initiate GLP-1 therapy themselves or coordinate with primary care and endocrinology colleagues. The framing matters: dermatologists are increasingly expected to recognize when a systemic metabolic intervention may support dermatologic goals, even when the prescription itself happens outside the specialty.

This sits within a broader shift. As GLP-1 use expands across large patient populations, dermatology is defining its own role — screening, counseling, and managing the skin implications of rapid weight loss and metabolic change, while clarifying where these drugs may complement standard psoriasis treatment.

Why now

The timing reflects momentum in the field. With GLP-1 agonists among the most widely prescribed drug classes in recent memory, specialty publications are moving to translate cardiometabolic data into dermatology-specific practice guidance — candidacy criteria first, prescribing logistics second.

For psoriasis management specifically, the practical takeaway is that metabolic health is no longer peripheral to the treatment plan. Clinicians reading the full Dermatology Times piece will find the decision framework for when to consider GLP-1 therapy in their psoriasis patients, and how to structure prescribing or referral around it.

Expect candidacy criteria and co-management pathways to sharpen as real-world dermatologic experience with incretin therapies accumulates.